RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Juwon Park to Piperazines

This is a "connection" page, showing publications Juwon Park has written about Piperazines.
Connection Strength

0.381
  1. Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Exp Hematol. 2010 Sep; 38(9):773-81.
    View in: PubMed
    Score: 0.343
  2. Kim KI, Park J, Ahn KS, Won NH, Kim BK, Shin WG, Yoon SS, Oh JM. Molecular characterization and prognostic significance of FLT3 in CML progression. Leuk Res. 2010 Aug; 34(8):995-1001.
    View in: PubMed
    Score: 0.021
  3. Kim BS, Bae E, Kim YJ, Ahn KS, Park J, Rhee JY, Lee YY, Kim Y, Lee D, Kim BK, Yoon SS. Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia. Anticancer Drugs. 2007 Jul; 18(6):641-7.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support